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e want to congratulate Nieuwlaat et al. (1) for their report from
he Euro Heart Survey, providing valuable insights into the
anagement of atrial fibrillation (AF) and heart failure (HF) in
aily clinical practice. They concluded that patients with AF and
F might be severely undertreated with regard to HF therapy and
ate control, referring to the guidelines for AF (2) and for HF (3).
evertheless, we are not sure whether these patients are always
ndertreated.
First of all, the investigators considered a combination of a
eta-blocker, angiotensin-converting enzyme inhibitor or angio-
ensin receptor blocker, and oral anticoagulation to be “the full
ackage” for AF and (systolic) HF. We want to emphasize,
owever, that it has never been established that beta-blockers
mprove morbidity and mortality in HF patients with AF. Indeed,
ost hoc analyses of the CIBIS II (The Cardiac Insufficiency
isoprolol Study II) and MERIT-HF (Metoprolol CR/XL Ran-
omized Intervention Trial in Congestive Heart Failure) studies
ere not able to demonstrate that beta-blockers decreased mor-
idity and mortality in HF patients that had AF (4,5). Certainly
rospective randomized trials are needed to elucidate whether
eta-blockers improve outcome in HF patients that are also known
ith AF, especially considering that these conditions often coexist.
Second, the investigators believed that 40% of patients with HF
nd permanent AF were receiving inadequate rate control because
hey had a resting heart rate of 80 beats/min, implying that 80
eats/min is the maximal target for rate control. Though this target
as been used before (6,7), there is no evidence as to which rate
ontrol target we should aim for. In fact, an analysis of patients
ith advanced HF demonstrated that outcome was similar in
atients who had a lower heart rate than 80 beats/min as in
atients who had a higher heart rate than 80 beats/min (8). The
ACE II (Rate Control Efficacy in Permanent Atrial Fibrillation)
tudy, investigating the optimal heart rate in permanent AF with
r without HF by randomizing patients to either strict (heart rate
80 beats/min and heart rate during minor exercise 110 beats/
in) or lenient (heart rate 110 beats/min) rate control, is much
waited for to clarify this clinically relevant issue (9).
In conclusion, the article by Nieuwlaat et al. (1) tells us much
bout daily clinical practice in treatment of patients with AF and
F, but it also emphasizes the need for evidence-based, unam-
iguous recommendations concerning beta-blocker use and rate
ontrol target in AF patients with HF.arcelle D. Smit, MD
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